In the present study, we investigated the activity of the thiazide-sensitive NCC (Na + -Cl − cotransporter) in experimental metabolic syndrome and the role of insulin in NCC activation. Renal responses to the NCC inhibitor HCTZ (hydrochlorothiazide), as a measure of NCC activity in vivo, were studied in 12-week-old ZO (Zucker obese) rats, a model of the metabolic syndrome, and in ZL (Zucker lean) control animals, together with renal NCC expression and molecular markers of NCC activity, such as localization and phosphorylation. Effects of insulin were studied further in mammalian cell lines with inducible and endogenous expression of this molecule. ZO rats displayed marked hyperinsulinaemia, but no differences in plasma aldosterone, compared with ZL rats. In ZO rats, natriuretic and diuretic responses to NCC inhibition with HCTZ were enhanced compared with ZL rats, and were associated with a decrease in BP (blood pressure). ZO rats displayed enhanced Thr 53 NCC phosphorylation and predominant membrane localization of both total and phosphorylated NCC, together with a different profile in expression of SPAK (Ste20-related proline/alanine-rich kinase) isoforms, and lower expression of WNK4. In vitro, insulin induced NCC phosphorylation, which was blocked by a PI3K (phosphoinositide 3-kinase) inhibitor. Insulin-induced reduction in WNK4 expression was also observed, but delayed compared with the time course of NCC phosphorylation. In summary, we report increased NCC activity in hyperinsulinaemic rodents in conjunction with the SPAK expression profile consistent with NCC activation and reduced WNK4, as well as an ability of insulin to induce NCC stimulatory phosphorylation in vitro. Together, these findings indicate that hyperinsulinaemia is an important driving force of NCC activity in the metabolic syndrome with possible consequences for BP regulation.
INTRODUCTION
In states of IR (insulin resistance), elevated plasma insulin levels develop due to resistance to insulin-stimulated glucose uptake in traditional sites of its actions, such as the skeletal muscle, liver or adipose tissue, and can act on various other tissues with harmful consequences [1] . The kidney is one of possible targets of these actions. Insulin receptors are expressed along the nephron, and insulin increases the reabsorptive activity of major renal sodium transporter proteins [2] . Indeed, the ability of insulin to stimulate sodium retention in the kidney [2, 3] has been shown to be unaffected [4] [5] [6] [7] or even increased in IR states [7] .
In affected individuals, IR develops as part of the metabolic syndrome, together with DM2 (Type 2 diabetes), truncal obesity, lipid abnormalities and hypertension [8] . Numerous experimental and clinical studies have investigated pathways that connect the metabolic syndrome with hypertension. However, the links between the mentioned metabolic factors and elevations of BP (blood pressure) remain elusive.
ZO (Zucker obese) rats, a model of the metabolic syndrome, IR and hyperinsulinaemia, display early (2-4 months of age) increases in the abundance of several sodium transporters [9, 10] . Our previous work [11] , in agreement with work by others [12] , has shown enhanced activity of the components of the insulin signalling cascade, such as Akt, in the kidney in hyperinsulinaemic models of IR. Insulin also activates SGK1 (serum-and glucocorticoid-induced protein kinase 1) in the distal nephron leading to antinatriuresis mediated by ENaC (epithelial Na + channel) via the IGF-I (insulin-like growth factor-I) receptor [13, 14] . These phenomena provide possible mechanisms for the development of hypertension in the metabolic syndrome.
The thiazide-sensitive NCC (Na + -Cl − cotransporter), the main sodium transporter in the DCT (distal convoluted tubule), is responsible for reabsorption of 3-7 % of filtered sodium load. NCC expression is limited to DCT cells both at the mRNA and protein level [15] . The NCC activity is modulated by aldosterone, AngII (angiotensin II), tonicity and tubular flow [16] [17] [18] [19] [20] [21] [22] . In addition, there is emerging evidence that NCC could be a target of insulin actions. Several studies conducted in different experimental conditions have suggested that insulin-induced increases in activity and/or abundance of NCC in the DCT may play a role in BP elevations in rodents [10, 21, 23, 24] . Taken together, these findings suggest that NCC activation in IR states may contribute to sodium retention.
Phosphorylation of NCC along its N-terminal cytoplasmic domain is essential for full cotransporter activity [17, 25, 26] . Studies conducted during the past decade have shown that the NCC is modulated by a signalling complex involving the WNK kinases. WNK modulate activity of SPAK (Ste20-related proline/alanine-rich kinase)/OSR1 (oxidative-stress-response kinase 1) [27] [28] [29] [30] , which in turn can directly phosphorylate NCC [17, 26] . WNK4 has attracted recent attention as a possible modulator of hormonal actions on NCC [18, 30, 31 ]. WNK4 appears to be able to exert either inhibitory or stimulatory effects on NCC, depending on the underlying physiological state and the level of AngII [32] . Additional lines of evidence have indicated that important intermediates in the insulin signalling cascade, such as Akt or SGK1, operate upstream of, or interact with, the WNK-SPAK/OSR1 signalling complex [18, 33] . Therefore it is likely that insulin induces NCC activity via phosphorylation on SPAK/OSR1-dependent residues.
In the present study, we tested the hypothesis that hyperinsulinaemia in IR states stimulates NCC activity by enhancing its phosphorylation at SPAK/OSR1-dependent sites. To address this issue, we determined NCC activity in hyperinsulinaemic ZO rats as compared with normo-insulinaemic lean control animals. Renal responses to the NCC inhibitor HCTZ (hydrochlorothiazide) were investigated as a measure of NCC activity in vivo in conjunction with renal abundance and membrane translocation of total and phosphorylated NCC, and expression of its modulators SPAK and WNK4. To directly determine whether insulin itself could participate in NCC phosphorylation, we reproduced the results in vitro in mammalian cell lines.
Part of this work was presented at the Renal Week of the American Society of Nephrology, held in San Diego, CA, U.S.A., from 27 October-1 November 2009 and subsequently published in an abstract form [33a] .
MATERIALS AND METHODS

Animals
Studies were performed in 16 ZO and 16 ZL (Zucker lean) rats, which do not display any metabolic defects. The animals were obtained from Charles River. ZO rats have a defect in leptin receptor that leads to hyperphagia and the development of obesity and IR within several weeks of age [34, 35] . The animals were housed with a 12 h light/12 h dark cycle, and with free access to food (standard chow) and water.
All experiments were carried out with the approval of, and in accordance with the regulations of the local Institute for Animal Care and Use Committee.
In vivo studies
The experiment was initiated in 10-week-old rats. The animals were administered with vehicle (0.9 % NaCl; 200 μl intraperitoneally) and placed into metabolic cages for 24-h collection of urine allowing measurements of U Na V (urinary excretion of sodium) and U K V (urinary excretion of potassium), as well as UF (urinary flow). This 24-h period was divided into two collection periods, allowing the measurements of early 0-3 h (09.00-12.00 h) and 4-24 h excretory responses. After completion of measurements in metabolic cages, the rats received a second dose of the vehicle and within 2 h underwent measurements of systolic BP by tail plethysmography as described previously [36] . The same day of the following week, the measurements were repeated in Insulin and Na + -Cl − co-transporter 637 a similar manner to assess the responses to HCTZ (3.75 mg/kg of body weight, intraperitoneally, in 200 μl of 0.9 % NaCl) before 24-h urine collection, followed by the second dose within 2 h before BP measurements, as a measure NCC activity in vivo. To account for hyperphagia, characteristic for the ZO rats, food intake was monitored during the urine collection periods as a possible confounding factor in renal excretory function studies. The experiment was completed by kidney harvesting for molecular studies at week 12.
Tissue harvesting for immunoblotting and immunofluorescence
The rats were anaesthetized with thiobarbiturate (100 mg/kg of body weight, intraperitoneally; Inactin; Sigma,) and the abdominal aorta was exposed via midabdominal incision. The aorta was cannulated with the PE-50 catheter 3-5 mm above the bifurcation, and the catheter was fed to the orifice of the left renal artery. The right renal artery was ligated and the right kidney was removed, decapsulated, divided into cortical and medullary portions, and snap frozen in liquid nitrogen for Western blot analysis. Left kidney was then perfused retrogradely with PBS/sucrose adjusted to 330 mOsm/kg of water, pH 7.4, for 20 s, followed by perfusion-fixation with 3 % (w/v) PFA (paraformaldehyde) in PBS for 5 min. After perfusion, the kidney was removed, cut transversely into 3 mm sections and cryopreserved overnight in 800 mOsm sucrose/PBS solution at 4
• C. The kidney sections were then snapfrozen in isopentane cooled with dry ice.
Cell culture and in vitro experiments
TTC (tetracycline)-inducible HEK (human embryonic kidney)--293 NCC cells cDNA encoding full-length mouse NCC was subcloned into the pcDNA5/FRT/TO vector (Invitrogen). FlpIn 293 host cells (Invitrogen) were cotransfected with the pcDNA5/FRT/TO-NCC construct and pOG44, a plasmid expressing Flp recombinase, resulting in a homologous recombination event. Transfected cells were screened for hygromycin resistance and lack of β-galactosidase activity. The Flp-In T-REx 293 NCC (FlpIn NCC) cell line was maintained in high-glucose DMEM (Dulbecco's modified Eagle's medium) containing 10 % FBS (fetal bovine serum), 200 μg/ml hygromycin, 15 μg/ml blasticidin and penicillin/streptomycin. NCC induction was confirmed by incubating the cells with or without TTC (1 μg/ml), followed by cell lysis and Western blotting. Endogenous expression of SPAK/OSR1 in HEK-293 cells was described previously [37] .
The cells were grown in insulin-free DMEM with 5.5 mM glucose, supplemented with 10 % fetal bovine serum and antibiotics. UI (uninduced) cells were harvested for Western blottings as negative controls. To study the effect of insulin on NCC phosphorylation, the cells were first stimulated with TTC to induce NCC expression. At 18 h after NCC induction, the cells were treated with insulin (40 ng/ml) and harvested after 10-360 min for further analyses by immunoblotting with anti-NCC and anti-phospho-NCC antibodies.
To explore further the insulin-induced signalling pathways leading to NCC phosphorylation, the effects of insulin were investigated as above in TTC-induced cells with or without pre-treatment with the PI3K (phosphoinositide 3-kinase) inhibitor LY294002 (60 min, 50 μM; Cayman Chemical Company).
MDCT (mouse DCT) cells
The MDCT cells (a gift from Professor Peter A. Friedman, Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA, U.S.A.) were used as another in vitro mammalian cell model, which displays endogenous NCC and WNK4 expression [38, 39] . The cells were stimulated with insulin for 20, 40 and 240 min with or without pre-treatment with PI3K inhibitor LY294002 (60 min, 50 μM). Additional analyses were conducted in cells 24-48 h after insulin stimulation and compared with cells grown in insulinfree media. The culture conditions and processing for further analyses was the same as in Flp-In-NCC cells. All in vitro studies were performed at least in quadruplicate.
Immunoblotting and immunofluorescence
The kidney cortical samples or cells were homogenized and processed to obtain whole-cell or crude membrane samples (100 000 g pellet) and analysed by immunoblotting as described previously [40] , using primary rabbit custom antisera directed against NCC (1:5000 dilution), anti-phospho-NCC, WNK4 (Phosphosolutions) [41] , C-SPAK (C-terminal SPAK) [42] , N-SPAK (N-terminal SPAK) [43] or rabbit primary antibodies raised against anti-phospho-Akt (Ser 473 ) (p-Akt; Cell Signaling Technology; 1:500 dilution), followed HRP (horseradish peroxidase)-conjugated secondary antibodies (Pierce). The phospho-NCC antibody recognizes phosphorylated Thr 53 of rat NCC, one of several functionally important sites of N-terminal phosphorylation [17, 26] . Visualization, loading control and image analysis were accomplished as described previously [40] .
The same rabbit antisera directed against NCC and phospho-NCC were used. Sets of 5 μm cryostat sections from pairs of ZL and ZO rats were processed in exactly the same fashion. The sections were washed three times in PBS before permeabilization in 0.5 % Triton-X in PBS for 30 min. The sections were again washed before being incubated with blocking medium, 5 % (w/v) nonfat dried skimmed milk powder in PBS (30 min), followed by primary antibodies diluted in blocking medium (1 h). Fluorescent secondary antibodies (Zymed-Invitrogen) 
Biochemical methods
Urinary sodium and potassium were measured by EL-ISE autoanalyser (Beckman). Plasma insulin and aldosterone concentrations were analysed by ELISA (ALPCO; Immuno-biological Laboratories). Blood glucose was measured using a reflectance meter (One Touch II; Lifescan).
Statistical analysis
Results are expressed as means + − S.E.M. Inter-group analyses were performed by ANOVA factorial with Bonferroni's post-hoc test. Two-way ANOVA was also applied to analyse further the effect of body type on phospho-NCC abundance in the renal cortex. Statistical significance was defined as a P < 0.05.
RESULTS
ZO rats display enhanced renal excretory response to HCTZ
General physical characteristics and metabolic/hormonal parameters are shown in Table 1 . At 12 weeks of age, ZO rats displayed increased body and kidney weight, and mild but significant increases in BG levels compared with ZL rats. Plasma insulin levels were markedly elevated in ZO rats, whereas plasma aldosterone concentrations were similar in ZL and ZO animals. The rates of U Na V during the vehicle administration and after HCTZ are shown in Figure 1 . There were no differences in U Na V between the ZL and ZO rats following the administration of a vehicle. HCTZ increased early U Na V (0-3 h) in both ZL and ZO rats, but the response was markedly enhanced in obese animals. Since the response to a diuretic is typically followed by a period of enhanced sodium reabsorption, we also analysed U Na V during the rest of the 24-h collection period (4-24 h). During this period, there were no differences in U Na V between the ZL and ZO rats after vehicle administration, but the difference in natriuretic response to HCTZ (right panels) between the groups was still apparent. The differences in early natriuresis (0-3 h) between the ZO and ZL animals were also present when the data were expressed as ratios per body weight.
Both early and 4-24 h UF and U K V following the vehicle administration were higher in ZO than in ZL rats (Figure 1 ). The effects of HCTZ on UF and U K V during the 0-3 h collection period followed the same pattern as U Na V with greater responses observed in ZO compared with lean counterparts. In addition, ZO rats demonstrated higher UF and U K V after HCTZ during the 4-24 h period. When adjusted for body weight, significantly higher diuretic and kaliuretic responses in ZO were observed only during the initial collection period.
The food intake during the control experiment (vehicle) was not different between the ZL (19 + − 2 g) and ZO (22 + − 2 g; P value = not significant) animals, but was significantly higher during the urine collection after the administration of HCTZ (17 + − 2 g in ZL rats compared with 32 + − 3 g in ZO rats; P < 0.05). During the early collection period (0-3 h.), all rats had negligible food intake and this factor did not influence observed differences in excretory responses to HCTZ. When adjusted for food intake, there were no differences in 4-24 h U Na V between the ZL and ZO rats both after the vehicle (54 + − 3 μmol/24 h per g of food in ZL rats compared with 70 + − 14 μmol/24 h per g of food in ZO rats) or HCTZ (54 + − 4 μmol/24 h per g of food in ZL rats compared with 42 + − 4 μmol/24 h per g of food in ZO rats) administration (P value = not significant), as well as in 24-h UF and U K V (results not shown).
Although BPs were similar in ZL and ZO animals at baseline, HCTZ treatment reduced BP only in ZO rats (P < 0.05; Figure 2 ).
Renal cortical NCC and WNK4
Although renal cortical NCC abundance was not different between the ZL and ZO rats, the abundance of NCC in crude membrane fractions was higher in obese than in lean animals ( Figures 3A and 3C ). The NCC phosphorylation at several threonine residues has been shown to be one of the mechanisms required for its activation [17] . The abundance of phospho-NCC (phosphorylated at Thr 53 ) was increased markedly in membrane fractions from ZO compared with ZL animals ( Figures 3B and 3C) ; a similar trend was observed in renal cortical whole cell homogenates (P = 0.07; Figures 3B and  3C) . When expressed as a ratio of phospho-to total NCC in corresponding samples, the differences between the ZL and ZO rats were apparent in both fractions ( Figure 3C ).
NCC activity can be regulated by insertion and removal from the apical membrane. Unlike the ZL rats, which displayed diffuse and more prominent cytoplasmic distribution of NCC, ZO rats demonstrated predominant apical membrane NCC distribution ( Figure 3D ). This pattern in lean and obese animals was even more apparent for phosphorylated NCC.
As described above, WNK4 and SPAK are known to regulate NCC activity [17, 26, 43] . Therefore the following analyses determined protein expression of these molecules. Immunoblotting using the antibody directed against the C-SPAK revealed several bands ( Figure 3E ). Densitometric analysis of all bands did not show any differences between ZL and ZO animals. In contrast, the band with the highest molecular mass (∼60 kDa), corresponding to FL-SPAK (full-length SPAK), was significantly more abundant in ZO rats ( Figure 3E ). The analysis of kidney homogenates using an antibody directed against N-SPAK, which detects only FL-SPAK [43] , revealed a weak signal at a molecular mass corresponding to this protein only in renal cortices from ZO, but not ZL rats ( Figure 3E ). As shown in Figure 3(F) , renal cortical WNK4 abundance was reduced in ZO rats compared with lean controls.
Effects of insulin on NCC and WNK4 in vitro
Having established the association of hyperinsulinaemia with increased NCC activity and phosphorylation in vivo in IR rats, we conducted further studies to provide direct evidence for insulin-induced phosphorylation of NCC in vitro.
The effects of insulin on NCC Thr 53/55 phosphorylation were first investigated in Flp-In NCC cells with inducible overexpression of NCC. As expected, NCC was not found in UI cells ( Figure 4A ). The cells induced by TTC were harvested at baseline and at subsequent time points indicated in Figure 4 (A). phospho-NCC was barely detectable at baseline. Insulin stimulation leads to a sustained phosphorylation of NCC detectable at 20 min after the stimulation (Figures 4A and 4B) . The abundance of total NCC remained stable during the observation period, resulting in an increase in the ratio of phospho-and total NCC apparent at 40 min after stimulation ( Figure 4B ). The Ser 473 phosphorylation of Akt kinase, a key molecule in the insulin signalling cascade [44] , was barely detectable in UI and in induced FlpIn NCC cells at baseline. Strong Akt phosphorylation was apparent already at 10 min after insulin stimulation and preceded the phosphorylation of NCC ( Figure 4C ). Insulin-induced NCC phosphorylation was markedly attenuated by pre-treatment with LY294002 ( Figures 4D  and 4E ), the inhibitor of PI3K, a kinase operating upstream of Akt in the insulin signalling cascade [44] . Insulin-induced Ser 473 phosphorylation of Akt was not detectable in LY294002-treated Flp-In NCC cells ( Figure 4F) .
Further experiments were performed in primary MDCT with endogenous expression of NCC and WNK4. The effect of insulin on NCC phosphorylation in MDCT reproduced the observations in Flp-In HEK-293 cells ( Figures 5A and 5B). Stimulation with insulin led to a gradual decrease in WNK4 protein expression with a significant difference after 240 min as compared with baseline ( Figure 5C ). The insulin-induced decrease in WNK4 was not detected in MDCT cells, which were pre-treated with LY294002 ( Figure 5D ). Lower WNK4 was detectable also after 24 and 48 h in insulin-treated cells when compared with time controls grown in insulin-free medium ( Figure 5E ).
DISCUSSION
The present results show that ZO rats exhibit enhanced natriuretic, diuretic and kaliuretic responses to NCC inhibition with HCTZ, as compared with their lean counterparts. These responses were associated with an increase in the abundance of NCC protein in crude membrane fractions in renal cortical samples from ZO rats, studied as one of surrogate markers of NCC activity [22, [45] [46] [47] . The ZO rats were studied at 10-12 weeks of age, i.e. at a pre-hypertensive stage, to avoid confounding effects of BP on baseline natriuresis. According to most studies, this model develops significantly elevated BP at 18-20 weeks of age [24] . Despite this fact, we observed BP-lowering effect of HCTZ in ZO, but not ZL, rats. At this early time point, a component of direct vasodilation may have contributed to the BP-lowering effect of HCTZ [48] . However, we consider early natriuresis the major driving force of the BP-lowering effect of HCTZ, as it was observed only in the ZO animals, which demonstrated strikingly enhanced natriuretic effects. We are not aware of data indicating enhanced vasodilator responses to HCTZ in resistance arteries in IR states.
Although these observations correspond with previous findings by others [10, 22, 24, [45] [46] [47] 49, 50] , in the present study, we also provide new evidence that NCC is activated further via phosphorylation in ZO animals the fully activated, membrane associated protein is the phosphorylated species [17] and that the abundance of phospho-NCC can be considered to be a marker of NCC activity [47] .
Compared with ZL rats, NCC phosphorylation in ZO rats was increased, in particular in membrane fractions. Moreover, localization of phospho-NCC in the DCT using immunofluorescence microscopy showed predominant apical membrane distribution in ZO rat kidneys, consistent with the active pool of the cotransporter. Taken together, these observations indicate enhanced NCC activity at this stage of the metabolic syndrome.
Despite the emerging evidence of altered regulation of the NCC in experimental metabolic syndrome, the nature of the upstream signals responsible for this phenomenon remains unknown. The pattern of NCC expression observed in the present study corresponds to other findings in in vivo studies exploring the effects of hormonal stimulators such as aldosterone [51] , AngII [20, 30, 51] or vasopressin [47] .
Previous studies have attempted to link increases in NCC activity in ZO rats to AngII actions [49] . The natriuretic responses to HCTZ were attenuated by AngII receptor blockade with candesartan, suggesting the contribution of the peptide to NCC activation. However, the sensitivity to candesartan was similar in ZO and ZL rats, indicating that, although the NCC is under the control of AngII, this mechanism is not specific for ZO rats and does not explain different responses to HCTZ between lean and obese rats. Aldosterone is another mediator that could participate in NCC activation in ZO rats, but the lack of differences in plasma aldosterone between the lean and obese animals does not support its role, at least in this model.
In 12-week-old ZO rats, hyperinsulinaemia appears to be the most prominent hormonal abnormality with respect to sodium handling. Several lines of evidence in hyperinsulinaemic IR rats suggest that NCC may be a direct target of insulin action. In normal rats, insulin infusion enhances natriuretic response to HCTZ [23] . Treatment with an insulin-sensitizing compound rosiglitazone, which reduces plasma insulin levels in ZO rats, reduces the natriuretic response to HCTZ, suggesting that the suppression of insulin levels reduces NCC activity [10] . Additionally, SGK1, which can be activated by insulin, may contribute to the enhanced expression and activation of the NCC [21, 50] .
A key signalling pathway that modulates NaCl reabsorption involves WNK kinases interacting with SPAK and OSR1 [17, [26] [27] [28] . In mammalian cells, SPAK phosphorylates and activates cation chloride cotransporters, including NCC [17, 26] . McCormick et al. [43] recently identified a KS-SPAK (kidney-specific SPAK) isoform, which lacks the kinase domain and inhibits NCC and NKCC phosphorylation by FL-SPAK in vitro. The KS-SPAK has been localized predominantly in TALH (thick ascending limb of Henle), whereas the FL-SPAK is more abundantly expressed along the DCT. These workers also reported a SPAK 'isoform switch' in response to sodium restriction [a state of NCC and NKCC2 (Na + -K + -Cl − co-transporter 2) activation] characterized by enhanced expression of FL-SPAK and suppressed KS-SPAK; these changes would be expected to facilitate NaCl reabsorption along both TALH and DCT.
In agreement with observations in the mouse kidney [43] , the present analysis revealed several SPAK bands also in rat kidneys. The FL-SPAK, which has been considered as the only form capable of phosphorylating NCC, was more abundant in ZO animals. The N-SPAK antibody has been used to identify the NCCstimulating component of SPAK (FL-SPAK), as other SPAK isoforms lack the recognized epitope. Although the signal detected from kidney tissue homogenates using this antibody is relatively weak, we detected a stronger 60-65 kDa band, corresponding to FL-SPAK, in ZO rat kidneys, suggesting that the more abundant kinaseactive, FL-SPAK contributes to the greater abundance of activated NCC. The band with the lowest molecular mass, detected using the C-terminal antibody in the present analysis, might correspond to KS-SPAK in mice.
Although not a focus of the present study, the mentioned isoform shift was apparent also in ZO rats ( Figure 3F , C-SPAK).
The role of WNK4 is still controversial, as both inhibitory and stimulatory effects on NCC have been proposed. Accordingly, some physiological perturbations that lead to decreases in NCC have been associated with increases in WNK4, whereas other stimuli, such as AngII infusion, appear to convert WNK4 from an inhibitory to a stimulatory state. In the present study, the more abundant phospho-NCC in ZO rats was associated with a lower abundance of WNK4; whether this difference is causal or consequential requires further study.
As the observations in rats are largely indirect and inferential, as whole animal responses to perturbation elicit multiple effects, we therefore tested effects of insulin on NCC in vitro, using two different mammalian cell models. The cells were stimulated with insulin at a concentration corresponding to average plasma insulin levels observed in ZO rats. The increase in phospho-NCC, together with activation of Akt kinase, a key molecule in insulin signalling cascade, was clearly apparent in the Flp-In NCC cells 20 min after insulin stimulation; this increase was sustained for at least 4 h. The effects of insulin on NCC were attenuated, and in the case of Akt abolished, by pre-treatment of cells with the PI3K inhibitor LY294002. This observation shows that PI3K/Akt operates upstream of NCC in the insulin-induced activation pathway. Notably, previous studies by others [12] and by our group [11] in IR hyperinsulinaemic rodent models have demonstrated increased renal Akt activity as compared with control animals, and its normalization by PI3K inhibition [11] .
The effects of insulin were further studied in MDCT cells with endogenous NCC and WNK4 expression. The results were similar to those observed in the Flip-In NCC cells, as insulin-treatment increased the abundance of phospho-NCC. Having observed a decrease in WNK4 in ZO rats, we sought to determine whether this phenomenon could be reproduced in insulin-stimulated cells. Indeed, the insulin stimulation that led to an increase in phospho-NCC abundance in MDCT cells also caused a decrease in WNK4 abundance; this was not observed in insulin-stimulated cells pre-treated with PI3K inhibitor. The decrease in WNK4 in response to insulin was rather delayed, however, as compared with Insulin and Na + -Cl − co-transporter 645 insulin-induced NCC phosphorylation. Consequently, it does not seem likely that a reduction in WNK4 causes the early NCC activation by the hormone, but suggests instead that WNK4 either helps maintain NCC in an activated state during chronic hyperinsulinaemia (in its inhibitory mode) or acts as a counter regulatory factor (in its stimulatory mode; see below). At this stage, we can only speculate about the mechanisms of insulin-induced WNK4 down-regulation, which seems to be too rapid to involve transcriptional events, but can involve protein degradation as described for other components of this pathway [52] .
Combining the in vitro experiments in mpkDCT cells with in vivo approaches in mice, Sohara et al. [53] have recently reported stimulatory effect of insulin on SPAK and NCC phosphorylation via PI3K. The effects of insulin were abolished in cells with SPAK or WNK4 knockdown, as well as in mice with SPAK deletion and in WNK4 hypomorphic mice. In most aspects, our observations are in accord with this report. It has been suggested that hormones, such as AngII [20, 30] or aldosterone [18] , activate NCC at least in part by converting WNK4 to an NCC-stimulatory mode. In this respect, our observation that phospho-NCC increases before any change in WNK4 abundance, and the report of Sohara and co-workers suggesting that WNK4 is necessary for the insulin-induced stimulation, together suggest that insulin may shift WNK4 to its stimulatory mode, in a manner analogous to AngII; in this case, the late decline in WNK4 abundance may be compensatory.
There are, however, important differences between these two studies that make direct comparison difficult: in vitro, Sohara et al. [53] stimulated the cells with 100 nM insulin, i.e. a concentration ∼100 times above the physiological range. In contrast, our experiments were conducted in cells stimulated with insulin concentrations found in hyperinsulinaemic animals (∼7-8 nM), which are already markedly elevated as compared with normal rats or humans. The impact of supraphysiological insulin levels on phosphorylation cascades leading to NCC activation may not reflect in vivo conditions. Our observations in rats reflect chronic hyperinsulinaemia, whereas the former study addressed acute effects of the hormone. Finally, the WNK4 hypomorphic mice are not true knockout animals and express portions of the WNK4 molecule that may be functional [54, 55] .
In summary, we report enhanced natriuretic, diuretic and BP responses to inhibition of the NCC in IR hyperinsulinaemic ZO rats as compared with lean counterparts. These responses were in ZO rats associated with molecular indicators of NCC activation, an increase in FL-SPAK expression and reduced expression of WNK4, a negative regulator of NCC. The stimulation of NCC-expressing cells in vitro with insulin at a concentration matching the plasma levels observed in ZO rats resulted in NCC phosphorylation mediated at least in part by Akt kinase and followed by a reduction in WNK4 expression, a pattern also observed in vivo. The findings indicate that hyperinsulinaemia is the major driving force of observed differences in NCC activity and expression between the ZL and ZO rats with possible consequences for BP regulation. A down-regulation of WNK4 may help to maintain NCC in an activated state during chronic hyperinsulinaemia.
CLINICAL PERSPECTIVES
r ln affected individuals, insulin resistance develops as part of the metabolic syndrome together with Type 2 diabetes, other metabolic abnormalities and hypertension. However, the links between the metabolic syndrome and hypertension remain unknown.
r In the present paper, we report that high plasma levels as a consequence of insulin resistance activate NCC in renal cells in vivo and in vitro and several signalling molecules involved in this process r Our results indicate that hyperinsulinaemia is an important driving force of NCC activity in the metabolic syndrome with possible consequences for BP regulation. The results also suggest future directions for research focusing on molecular targets for the treatment of hypeftension in patients with the metabolic syndrome.
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